Core Viewpoint - Sanofi China announced that its candidate 21-valent pneumococcal polysaccharide conjugate vaccine (referred to as "PCV21 vaccine") developed in collaboration with SK Bioscience has received approval from the National Medical Products Administration (NMPA) to initiate clinical research [1] Group 1 - The PCV21 vaccine is the world's first candidate product for a 20-valent or higher pneumococcal polysaccharide conjugate vaccine to enter Phase III clinical trials for infants and young children [1] - The vaccine has already conducted corresponding Phase III clinical trials in various populations globally prior to this approval [1]